First Opinion John E. Osborn Biologics lose protection as U.S.-Canada-Mexico trade agreement moves forward
Business Sharon Begley STAT Plus: Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own
First Opinion Jonathan Kimball Trade agreement drug monopoly is obsolete given faster, better drug discovery
First Opinion Carlos Sattler and Sheila Frame Biosimilar approval and adoption in the U.S. needs to be expedited
First Opinion William Feehery and Julie Bullock STAT Plus: Three steps can help companies speed FDA approval of new drugs
First Opinion William S. Smith STAT Plus: The Biden administration needs to look beyond ICER for evaluating drug therapies
Pharmalot Ed Silverman STAT Plus: Will the ‘patent dance’ cause Amgen to temporarily pull a biosimilar off the market?
Biotech Elizabeth Cooney STAT Plus: Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it
Politics Erin Mershon STAT Plus: Drug makers jostle over potential Medicare changes in congressional spending deal
First Opinion Michelle Hoffmann Biosimilars: the cure for sky-high drug prices or a stake in the heart of innovation?
Pharmalot Ed Silverman STAT Plus: Court ruling on biosimilar launches could increase health care costs
Pharmalot Ed Silverman Unintended twist in Obamacare may cost some Medicare patients more for biosimilars